Syndax Pharmaceuticals (SNDX) Payables (2016 - 2025)
Historic Payables for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $13.8 million.
- Syndax Pharmaceuticals' Payables rose 18227.85% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 18227.85%. This contributed to the annual value of $11.6 million for FY2024, which is 1671.52% up from last year.
- Per Syndax Pharmaceuticals' latest filing, its Payables stood at $13.8 million for Q3 2025, which was up 18227.85% from $17.4 million recorded in Q2 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Payables peaked at $17.4 million during Q2 2025, and registered a low of $3.6 million during Q2 2021.
- For the 5-year period, Syndax Pharmaceuticals' Payables averaged around $8.4 million, with its median value being $8.1 million (2023).
- As far as peak fluctuations go, Syndax Pharmaceuticals' Payables tumbled by 2743.94% in 2021, and later skyrocketed by 18227.85% in 2025.
- Syndax Pharmaceuticals' Payables (Quarter) stood at $5.7 million in 2021, then decreased by 23.27% to $4.4 million in 2022, then skyrocketed by 128.99% to $10.0 million in 2023, then grew by 16.72% to $11.6 million in 2024, then rose by 18.92% to $13.8 million in 2025.
- Its last three reported values are $13.8 million in Q3 2025, $17.4 million for Q2 2025, and $10.0 million during Q1 2025.